quetiapin "accord" 200 mg filmovertrukne tabletter
accord healthcare b.v. - quetiapin fumarat - filmovertrukne tabletter - 200 mg
quetiapin "accord" 300 mg filmovertrukne tabletter
accord healthcare b.v. - quetiapin fumarat - filmovertrukne tabletter - 300 mg
orgovyx
accord healthcare s.l.u. - relugolix - prostatiske neoplasmer - endokrine terapi - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. virkning af imatinib om resultatet af bone marrow transplantation er ikke fastlagt. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. erfaringerne med imatinib i patienter med mds/mpd, der er forbundet med pdgfr gen re-arrangementer er meget begrænset. der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.
buspiron "actavis" 10 mg tabletter
actavis group ptc ehf. - buspironhydrochlorid - tabletter - 10 mg
exemestan "accord" 25 mg filmovertrukne tabletter
accord healthcare b.v. - exemestan - filmovertrukne tabletter - 25 mg
ciclosporin "actavis" 100 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 100 mg
ciclosporin "actavis" 25 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 25 mg
ciclosporin "actavis" 50 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 50 mg
sandimmun neoral 100 mg kapsler, bløde
novartis healthcare a/s - ciclosporin - kapsler, bløde - 100 mg